Latest / Pharmacy Podcast Network / 10 Years of Biosimilars: A Decade of Progress and a Bright Future | Cardinal Health™ Counter Talk™ Podcast
Transcript
- 0:05Speaker 1: You are listening to the global network of podcasters dedicated
- 0:09Speaker 1: to the pharmacy profession. Welcome to the Pharmacy Podcast Network.
- 0:21Speaker 2: The testimonials appearing in this podcast reflect individual experiences, and
- 0:24Speaker 2: individual results may vary. Cardinal health is not claimed, or
- 0:27Speaker 2: should the listener assume that any individual experience recounted in
- 0:30Speaker 2: this podcast is representative of what another consumer may experience.
- 0:40Speaker 2: The Cardinal Health caunter Talk podcast and collaboration with Pharmacy
- 0:43Speaker 2: Podcast Network, is for independent pharmacists to learn about the
- 0:46Speaker 2: state of the industry, innovative services and solutions, and the
- 0:49Speaker 2: future of pharmacy. Join me your host Jason colorI for
- 0:53Speaker 2: conversations with pharmacists, cardinal health leaders, and industry experts, sharing
- 0:57Speaker 2: best practices, discussing industry trends, and showcasing cardinal health products
- 1:01Speaker 2: and services. You can subscribe to the Cardinal Health counter
- 1:04Speaker 2: Talk podcast on Spotify, Apple Podcasts, and wherever you listen
- 1:08Speaker 2: to your favorite podcasts. Hello everyone, and welcome back to
- 1:11Speaker 2: the Cardinal Health counter Talk podcast. I'm your host Jason colorI,
- 1:14Speaker 2: and today we have a really interesting show getting into
- 1:18Speaker 2: biosimilars and the year twenty twenty five, marking ten years
- 1:22Speaker 2: since biosimilars first came into the market. Now, in this episode,
- 1:25Speaker 2: we will be talking to Dracy por, director of biosimilars
- 1:28Speaker 2: here at Cardinal Health, to give us a bit of
- 1:30Speaker 2: a reintroduction to biosimilars, learn about their genesis, their evolution,
- 1:35Speaker 2: and how they are being utilized today within the healthcare landscape.
- 1:38Speaker 3: Welcome to the show, Dracy, Hi.
- 1:40Speaker 1: Jason, thank you so much for having me. I'm excited
- 1:43Speaker 1: to be here.
- 1:44Speaker 3: I'm excited to talk to you as well.
- 1:46Speaker 2: It's been quite a while since we did an episode
- 1:48Speaker 2: on biosimilar so I'm really interested to know how biosimilars
- 1:52Speaker 2: has evolved over the last several years and since its
- 1:54Speaker 2: inception back in twenty fifteen. But before we get into that, Dracy,
- 1:58Speaker 2: why don't you tell us a little bit about yourself.
- 2:00Speaker 1: Sure. So, like you said, I'm the director of Biosimilars.
- 2:04Speaker 1: I actually have been in the biosimilar industry since twenty fifteen,
- 2:11Speaker 1: since our inception of commercialization here in the United States.
- 2:15Speaker 1: So not only is the biosimilar industry ten years old,
- 2:19Speaker 1: I'm celebrating ten years of being in the same industry myself,
- 2:22Speaker 1: so it's been quite a milestone. I love to see
- 2:26Speaker 1: the evolution and the progress that we've made in this market,
- 2:30Speaker 1: how much we've done for the healthcare ecosystem for patients.
- 2:34Speaker 1: It's an exciting time, all.
- 2:36Speaker 3: Right, So we're celebrating two things today then, right, is
- 2:38Speaker 3: that what.
- 2:39Speaker 2: We're talking about? Yeah? All right, Well let's get into it.
- 2:45Speaker 2: So we just talked about that. Twenty twenty five marks
- 2:48Speaker 2: ten years since the biosimilar has come to market. But first,
- 2:54Speaker 2: why don't we do a quick explanation of what a
- 2:57Speaker 2: biosimilar is for anyone that's unaware of it is, just
- 3:00Speaker 2: to kind of give a little bit of a reintroduction,
- 3:02Speaker 2: that'd be great.
- 3:04Speaker 1: Well, I think I'm going to start with the FDA definition, right,
- 3:07Speaker 1: I think that's a good starting point to understand biosimilarity.
- 3:11Speaker 1: The FDA defines a biosimilar as a biological product that's
- 3:16Speaker 1: highly similar to a reference product, notwithstanding minor differences in
- 3:21Speaker 1: terms of like safety, purity, impotency. But the way this
- 3:26Speaker 1: even occurs is a biologic and I will explain what
- 3:30Speaker 1: a biologic is as well in a minute. But when
- 3:32Speaker 1: a biologic loses patent protection, other pharmaceutical manufacturers can use
- 3:38Speaker 1: the three fifty one K pathway to produce a product
- 3:42Speaker 1: that is highly similar. Once that product is approved, it
- 3:46Speaker 1: is a biosimilar. Now, biologics are different than when you
- 3:51Speaker 1: think of a pill type of medication. Biologics are usually
- 3:56Speaker 1: injected or infused, and non biologics are typically or all.
- 4:01Speaker 1: Biologics are complex, large molecules. They're produced from living organisms,
- 4:06Speaker 1: whereas if you think of a pill medication, which is
- 4:09Speaker 1: where generics originate, they're smaller, they're simple molecules. They're just
- 4:14Speaker 1: chemically synthesized in a lab. They're not as complex to create,
- 4:19Speaker 1: which is why biologics have a biosimilar regulatory pathway for
- 4:23Speaker 1: approval and why they're different from other products on the market.
- 4:28Speaker 2: Okay, so get into the pathway you're talking about. How
- 4:32Speaker 2: does that work?
- 4:34Speaker 1: So the three P fifty one K pathway is a
- 4:37Speaker 1: pathway specific for biosimilars, and it is different. It minimizes
- 4:42Speaker 1: the investment because the required clinical trials look different than
- 4:48Speaker 1: the originator biologic. It also reduces the time it takes.
- 4:54Speaker 1: Biosimilar can come to market for between one hundred and
- 4:56Speaker 1: three hundred million, which is substantially less than the orig
- 5:00Speaker 1: genator biologic, and six to ten years, which is also
- 5:03Speaker 1: substantially less than the originator of biologic, So it's an
- 5:08Speaker 1: abbreviated pathway. It's a shortened and condensed version. Because this
- 5:12Speaker 1: product is showing it's highly similar to the originator, it's
- 5:16Speaker 1: not showing and proving clinical efficacy as rigorously as the
- 5:22Speaker 1: originator product had to, So they have a different pathway
- 5:26Speaker 1: to approval. And it's been interesting because they still they
- 5:30Speaker 1: still do a lot of phase three trials, they still
- 5:34Speaker 1: do a lot of clinical work, but they're really just
- 5:36Speaker 1: trying to show that they're highly similar and they don't
- 5:39Speaker 1: have any immunogenicities in the body, and that has saved
- 5:43Speaker 1: manufactures time and money bringing these additional cost effective treatment
- 5:48Speaker 1: options to the market.
- 5:50Speaker 3: Interesting.
- 5:50Speaker 2: So let's get into a little bit about why biosimilars
- 5:54Speaker 2: are important to healthcare because in a state of mind
- 5:57Speaker 2: where people will will just maybe revert back to well,
- 6:00Speaker 2: I'm just going.
- 6:01Speaker 3: To wait for the generic.
- 6:03Speaker 2: Why are biosimilars so important to healthcare these days compared
- 6:07Speaker 2: to where they were?
- 6:08Speaker 1: Sure, so biologics will never have generics, so this is
- 6:14Speaker 1: their chance. That's biosimilars are super important healthcare because we're
- 6:19Speaker 1: increasing access to effective treatments. This is your opportunity to
- 6:24Speaker 1: have other treatment options in the space of biologics. They
- 6:28Speaker 1: reduce costs, They promote competition in the market. Biosimilars increase
- 6:34Speaker 1: the range of available therapies, which gives our providers in
- 6:37Speaker 1: patients more choices with high standards of care. Because these
- 6:41Speaker 1: products won't ever have generics. This really is the opportunity
- 6:44Speaker 1: to have other options that could possibly be more cost effective.
- 6:48Speaker 1: Biosimilars that lower price tag that they have in the
- 6:53Speaker 1: last decade, which is one of our celebratory moments, they've
- 6:57Speaker 1: saved thirty six billion dollars one decade. Wow, those are
- 7:02Speaker 1: significant savings. And the exciting thing about those savings is
- 7:06Speaker 1: they can be reinvested into the market to fund future innovation.
- 7:11Speaker 2: Well, it's pretty incredible to hear, especially that cost savings.
- 7:14Speaker 2: That's a that's not a small number, and I feel like,
- 7:18Speaker 2: I think, to your point, the opportunity is just there
- 7:21Speaker 2: for the taking.
- 7:22Speaker 3: So that's pretty exciting.
- 7:24Speaker 2: As we spoke about earlier when we did the introduction,
- 7:27Speaker 2: twenty twenty five is ten years since the first biosimilar
- 7:30Speaker 2: came to market. What does this mean to you personally
- 7:34Speaker 2: for the market overall? And I also want to get
- 7:37Speaker 2: a little bit of your cardinal health perspective. What is
- 7:39Speaker 2: this really done for cardinal health? Where something maybe had
- 7:42Speaker 2: started out as an idea, something that we want to
- 7:45Speaker 2: get into, and now ten years later, what the perspective.
- 7:49Speaker 3: Is now sure?
- 7:51Speaker 1: So this ten year mark truly is a celebration. It
- 7:55Speaker 1: is a significant milestone for the healthcare ecosystem, reflecting progress,
- 8:01Speaker 1: meaning those savings that have been actualized, and some ongoing
- 8:06Speaker 1: challenges to adoption. So it's both sides, right, it's progress
- 8:11Speaker 1: and the acceptance and realization of challenges and deciding how
- 8:16Speaker 1: to move forward and what we need to do. The
- 8:19Speaker 1: last ten years have built a really strong foundation for
- 8:23Speaker 1: the biosimilar industry. We haven't unleashed the full impact of
- 8:27Speaker 1: biosimilars in the market, but we've built a strong foundation
- 8:31Speaker 1: and the next ten years are exciting. We'll see what
- 8:34Speaker 1: we can do. We can unleash this impact. We can
- 8:37Speaker 1: create more savings, bring more competition and treatment choices to
- 8:41Speaker 1: the market. But the market has learned a lot over
- 8:44Speaker 1: the last decade. Biologics account for only two percent of prescriptions,
- 8:49Speaker 1: so you might think, wow, that's not that much. Where
- 8:51Speaker 1: are we focused here? Well, that two percent of prescriptions
- 8:55Speaker 1: is actually almost forty percent of medication spend. It's just
- 9:00Speaker 1: over thirty seven percent, So while it's two percent of prescriptions,
- 9:05Speaker 1: it's thirty seven percent of spend. In twenty twenty three,
- 9:10Speaker 1: the US spent two hundred and sixty billion dollars on
- 9:13Speaker 1: biologic medication, So this is an extremely significant area of
- 9:19Speaker 1: spend that we have to find a way to draw savings,
- 9:22Speaker 1: and biosimilars are one of the only options. That's why
- 9:25Speaker 1: there's so much focus and importance on this market. Another
- 9:30Speaker 1: thing that's super important about biosimilars is that they've en
- 9:34Speaker 1: abled nearly three hundred and forty four incremental days of
- 9:38Speaker 1: therapy that would not have occurred without lower costs driven
- 9:42Speaker 1: by these products. It's extremely significant and important for patients
- 9:48Speaker 1: for the system from a savings perspective, and you know,
- 9:52Speaker 1: that is why this market is important to Cardinal Health
- 9:55Speaker 1: and why Cardinal Health is working to educate about these
- 10:00Speaker 1: cost effective treatment options and provide support to customers. We
- 10:04Speaker 1: have our website that is available to the public and
- 10:07Speaker 1: that has an enormous amount of resources. We've collected FDA
- 10:11Speaker 1: resources and other cardinal health resources on that website to
- 10:14Speaker 1: help drive that awareness and drive that education because we
- 10:18Speaker 1: see that need to bring the savings to the system
- 10:21Speaker 1: to fund the future.
- 10:23Speaker 2: When you talk about cost savings, because these are big numbers,
- 10:27Speaker 2: can you give us a little bit of an overview
- 10:29Speaker 2: who exactly overall is getting these cost savings? Is it manufacturers?
- 10:36Speaker 2: Is it the doctors, is it the patients? Just give
- 10:39Speaker 2: us a little bit of an overview of where all
- 10:41Speaker 2: the savings is hitting.
- 10:43Speaker 1: Yeah, I would say the savings is hitting the system
- 10:46Speaker 1: right because prices are coming Prices are coming down, both
- 10:49Speaker 1: innovator prices and biosimilar prices. So it's just less spend
- 10:54Speaker 1: in the medica the biologic medication basket, but there are
- 10:58Speaker 1: benefits that trickle down on two patient level. For example,
- 11:02Speaker 1: Medicare beneficiaries, they're estimated to save two thousand dollars each
- 11:08Speaker 1: in potential out of pocket costs due to biosimilar competition,
- 11:12Speaker 1: because biosimilars have the ability to reduce costs and curb
- 11:18Speaker 1: price escalation. So maybe the biosimilar isn't the only product
- 11:23Speaker 1: that's had a price decrease, Maybe the originator has had
- 11:26Speaker 1: a price decrease or maybe just its curved price escalation.
- 11:30Speaker 1: So because of that, it is drawing in savings, and
- 11:34Speaker 1: CMS has been able to state that there is potential
- 11:37Speaker 1: savings for out of pocket costs due to this competition
- 11:41Speaker 1: in the marketplace. So we do know that there are
- 11:43Speaker 1: many different stakeholders that are receiving benefits from the biosimilar business.
- 11:51Speaker 2: You mentioned a little bit ago about the US government
- 11:54Speaker 2: playing a role in the availability of biosimilar is Can
- 11:58Speaker 2: you get a little bit into that and maybe elaborate
- 12:01Speaker 2: more on how this and the role of the US
- 12:04Speaker 2: government has affected Cardinal Health and our role in bringing
- 12:08Speaker 2: biosimilars to the market as well.
- 12:10Speaker 1: Sure, there have been many, or i should say several
- 12:14Speaker 1: key regulatory shifts in the last decade that have impacted
- 12:17Speaker 1: biosimilars and Cardinal Health's ability to bring those biosimilars into
- 12:22Speaker 1: the hands of our customers and essentially into the hands
- 12:25Speaker 1: of our patients. So in twenty ten, the Affordable Care
- 12:29Speaker 1: Act created that abbreviated approval pathway for biosimilars that you
- 12:33Speaker 1: and I discussed at the very beginning of our conversation,
- 12:38Speaker 1: and then the BPCIA, which is the Biologics Price Competition
- 12:43Speaker 1: and Innovation Act, also in twenty ten, created a regulatory
- 12:47Speaker 1: approval process for biosimilars, so we got an abbreviated approval pathway,
- 12:53Speaker 1: a regulatory approval process, and then in twenty fifteen, we
- 12:58Speaker 1: had our first bio similar commercialized in the United States,
- 13:02Speaker 1: Zarzeo launched. So those regulatory frameworks enabled that first drug
- 13:08Speaker 1: to hit the market. In twenty twenty two, we saw
- 13:10Speaker 1: the Inflation Reduction Act, which aims to decrease drug costs,
- 13:14Speaker 1: which aligns with biosimilars. Congress does continue to try and
- 13:19Speaker 1: move the needle with the Red Tape Elimination Act, which
- 13:22Speaker 1: is an act that would deem all products interchangeable. And
- 13:28Speaker 1: if you're looking at what impact regulation has had, well
- 13:32Speaker 1: with that first launch in twenty fifteen, if you look
- 13:36Speaker 1: to today twenty twenty five, there are over seventy two
- 13:40Speaker 1: approved biosimilars, so that indicates the success of this regulatory process.
- 13:47Speaker 1: We've been able to bring over seventy products to an
- 13:50Speaker 1: approved state within the US market, So that is how
- 13:57Speaker 1: the regulation has enabled Cardinal Hall to get products into
- 14:01Speaker 1: the hands of the customers.
- 14:03Speaker 2: Wow, that's a lot of information there, I mean, it's astounding.
- 14:06Speaker 2: How I'm trying to remember when I first had that chat,
- 14:11Speaker 2: way back when how many were approved, and now you're
- 14:15Speaker 2: saying today.
- 14:15Speaker 3: We're over what you say, twenty two.
- 14:18Speaker 2: Seventy two seventy two different biosimilars.
- 14:20Speaker 3: That's incredible.
- 14:23Speaker 2: I want to get into now, as we've talked about
- 14:27Speaker 2: the beginning of biosimilars, the pathway, everything that's kind of
- 14:31Speaker 2: led up to now, the government being involved, and how
- 14:34Speaker 2: we're seeing this evolution.
- 14:35Speaker 3: What about the future of biosimilars.
- 14:38Speaker 2: You talked about retinas and those biosymlers being introduced in
- 14:41Speaker 2: twenty twenty one. With this landscape evolving, what do you
- 14:46Speaker 2: think healthcare decision makers should be anticipating in the future
- 14:50Speaker 2: when it comes to biosimilars.
- 14:53Speaker 1: Yeah, so let's talk about Retina just a little bit.
- 14:56Speaker 1: And as we lead into that, because we did focus
- 14:58Speaker 1: a lot on Retna in our Biosimilars report that we're
- 15:02Speaker 1: celebrating our decade piece, because the retina market is a
- 15:06Speaker 1: huge piece of the future and it's fairly new. If
- 15:10Speaker 1: we look at this timeline of the retina market, it's
- 15:16Speaker 1: significant for biosimilars because this is one of the first
- 15:19Speaker 1: times biosimilars have become mainstream. As we're evolving into Retna
- 15:24Speaker 1: and now the summer will be evolving into bone health.
- 15:28Speaker 1: The retina market is interesting because it has shown it
- 15:33Speaker 1: isn't a fest uptake market, which is similar to oncology,
- 15:38Speaker 1: and maybe that wasn't really anticipated. It's exciting and it
- 15:43Speaker 1: means that there's opportunity for other therapeutic areas to see
- 15:47Speaker 1: quick uptake in the market. So for retina, the first
- 15:51Speaker 1: FDA approvals were in twenty twenty one. We had launches
- 15:55Speaker 1: in twenty twenty two, more approvals in twenty four. Also
- 16:00Speaker 1: in twenty four what we saw was the randombism ad
- 16:04Speaker 1: biosimilars reaching a fifty five percent share three years post launch.
- 16:09Speaker 1: That's exciting. That's really more common in oncology, where we
- 16:14Speaker 1: see a lot of acceptance. So I think that the
- 16:18Speaker 1: takeaway here is there's real opportunity with retina. It's exciting.
- 16:22Speaker 1: When you ask what do I think all everyone should
- 16:25Speaker 1: expect with the future, Well, in retina, I think all
- 16:28Speaker 1: stakeholders should expect increase treatment options and decreasing costs because
- 16:34Speaker 1: of all these products that have been approved and are
- 16:36Speaker 1: starting to launch into the market. I also think they
- 16:40Speaker 1: should expect to focus on education. And the reason I
- 16:43Speaker 1: say that is because in a survey that we did
- 16:47Speaker 1: and some interviews that we performed with retina specialists for
- 16:51Speaker 1: our Biosimilars report here at Cardinal Health, we identified a gap.
- 16:56Speaker 1: An interview that we did with a retina specialist uncovered
- 17:01Speaker 1: that one in every one hundred patients in his retina
- 17:05Speaker 1: practice knows what a biosimilar is. So I think that's
- 17:09Speaker 1: a huge, huge takeaway for the next decade is we
- 17:13Speaker 1: need to continue to focus on education and as biosimilars
- 17:17Speaker 1: launch into new therapeutic areas like retina, like bone health,
- 17:22Speaker 1: that means new patients, it could mean new providers, So
- 17:26Speaker 1: that mission of education it never ends. It's a whole
- 17:30Speaker 1: new subset of people that we need to teach and
- 17:34Speaker 1: provide awareness to.
- 17:36Speaker 2: So retinopathy, which is kind of the treatment of you know,
- 17:39Speaker 2: for the retina, is usually from what I've read it
- 17:42Speaker 2: it's therapeutic. It usually stems from diabetes and diabetic health issues.
- 17:50Speaker 3: Is that is that accurate?
- 17:52Speaker 1: Some do? Yeah, I mean it's macular degeneration. Could also
- 17:55Speaker 1: be you know, age related, but yes, there are a
- 17:58Speaker 1: few illnesses that could lead to this type of necessity
- 18:04Speaker 1: for medication and indicating from an indication perspective, it's also
- 18:09Speaker 1: a sensitive area. It's the eye, it's an injection in
- 18:12Speaker 1: the eye. There's a lot of education needed when you
- 18:15Speaker 1: reach a new market like that, and you know, it's
- 18:18Speaker 1: a scary space. It's your eye, it's the vision, it's
- 18:21Speaker 1: you know. I think that I think that we learned
- 18:24Speaker 1: a lot from the survey and from the interviews we've
- 18:29Speaker 1: done in the retina space, and we are working really
- 18:31Speaker 1: hard to continue to provide education and awareness in the
- 18:34Speaker 1: retina market because of the results of what we have
- 18:37Speaker 1: put together through our reports.
- 18:40Speaker 2: So as far as the challenges that we're seeing with biosimilars,
- 18:43Speaker 2: I remember, you know, back when talking about it, it
- 18:46Speaker 2: was it was there's a high cost of development, but
- 18:51Speaker 2: you're also saying that there is a significant savings that
- 18:53Speaker 2: comes along with that, you know, once once it hits
- 18:56Speaker 2: the market. So what challenges did biosimilars have at the
- 19:00Speaker 2: start and the introduction ten years ago to what we're
- 19:04Speaker 2: seeing today.
- 19:07Speaker 1: So that's a really good point, and that was the
- 19:10Speaker 1: same question that I had, and so we did create
- 19:15Speaker 1: some research in the decade piece around barriers. When we
- 19:21Speaker 1: set out to create content for this decade piece, I said,
- 19:25Speaker 1: I want to know from our customers if the barriers
- 19:29Speaker 1: are better than they were when this market started ten
- 19:33Speaker 1: years ago? Are they worse? Are they the same. I'd
- 19:36Speaker 1: like to see how the practices have evolved with the
- 19:39Speaker 1: biosimilar market, just not how I see the evolution. Oh,
- 19:43Speaker 1: we have seventy two products. What is it like for
- 19:46Speaker 1: our practice, our practices, our providers, our health business partners.
- 19:51Speaker 1: So we had some amazing interviews and we learned quite
- 19:55Speaker 1: a bit from the oncology side of the business. And
- 20:00Speaker 1: what we learned is that they've identified two types of barriers,
- 20:03Speaker 1: and I'll share that with you because I think it's
- 20:04Speaker 1: impactable to hear. They are economic and noneconomic barriers. The
- 20:09Speaker 1: economic barriers included reiinforsement policies and pricing dynamics. The non
- 20:15Speaker 1: economic barriers were provider and patient awareness, which we at
- 20:19Speaker 1: Cardinal Health have made a strategic priority, inventory management, and
- 20:25Speaker 1: benefit investigation processes. And I think these barriers all still
- 20:29Speaker 1: exist today in some way, shape or form. I think
- 20:32Speaker 1: it just depends on the stakeholder. For example, some offices
- 20:36Speaker 1: have really tight revenue cycle management, which you would find
- 20:40Speaker 1: in our article with Marlow blazon, and they've mastered on
- 20:44Speaker 1: time ordering, which has alleviated a lot of these barriers,
- 20:47Speaker 1: but while other stakeholders they may still struggle with these barriers.
- 20:52Speaker 1: And I think there's value in sharing that article because
- 20:55Speaker 1: maybe some practices can learn from this practice that has
- 20:58Speaker 1: found a way to make biosimilar adapt effective for them.
- 21:02Speaker 1: So I think there's value in sharing best practices, good stories,
- 21:05Speaker 1: what works. That's what we've tried to do the last
- 21:07Speaker 1: couple of years with our Biosimilarity Report, is share learnings
- 21:11Speaker 1: that could maybe help other practices find ways to benefit
- 21:15Speaker 1: from this opportunity.
- 21:17Speaker 2: Yeah, real real time stories and people that are actually
- 21:19Speaker 2: doing it out in the market and telling those stories.
- 21:22Speaker 2: It seems to be the best way to communicate those
- 21:26Speaker 2: types of situations. So eager to it'll be a great resource.
- 21:30Speaker 2: We'll talk about that in a little bit here.
- 21:31Speaker 3: But with the.
- 21:33Speaker 2: Challenges that we're talking about here in the near future
- 21:38Speaker 2: and the long term future, any of those challenges still
- 21:42Speaker 2: exist today that you saw in the beginning that we're
- 21:45Speaker 2: seeing now.
- 21:47Speaker 1: There are some challenges that are the same. In some markets,
- 21:51Speaker 1: we're not seeing that fast uptake like what I mentioned
- 21:55Speaker 1: we're seeing with retina, or we're seeing with oncology. Some
- 21:57Speaker 1: of the uptakes and maybe rheumatology. That market adoption has
- 22:02Speaker 1: taken a little longer to get a good share of
- 22:06Speaker 1: the patients, and there's been a lot of learnings there.
- 22:10Speaker 1: There are still some barriers with benefits investigations or the
- 22:15Speaker 1: operational piece for practices. Switching from one product to another
- 22:21Speaker 1: requires a new prior off maybe running a benefit investigation,
- 22:27Speaker 1: checking into the patient's payer requirements, and it's just administrative burden.
- 22:33Speaker 1: Some of those barriers have not gone away, and maybe
- 22:37Speaker 1: they won't. Maybe what we do is just continue to
- 22:39Speaker 1: support those customers through those administrative barriers because it's how
- 22:45Speaker 1: the system works, and they're not all able to be
- 22:48Speaker 1: completely alleviated.
- 22:50Speaker 3: Got it.
- 22:50Speaker 2: So with biosymom's growing so fast at least right now,
- 22:54Speaker 2: what do you think the future for biosimilars is? Even
- 22:57Speaker 2: if we talk short term maybe the next ten years,
- 23:01Speaker 2: or long term down the line, where do you see
- 23:03Speaker 2: it going?
- 23:05Speaker 1: I think the future for biosimilars is bright, whether you're
- 23:08Speaker 1: looking at short term or long term. So for short term,
- 23:12Speaker 1: we're seeing increased treatment options, we're seeing significant savings. Like
- 23:15Speaker 1: I said, we're already at thirty six billion. We are
- 23:18Speaker 1: seeing improved payer acceptance. Payers are adding biosimilars to formulary
- 23:25Speaker 1: much faster after launch than they did ten years ago.
- 23:28Speaker 1: We're seeing many more biosimilars winning coverage, and that is
- 23:34Speaker 1: showing that short term is a bright future for us,
- 23:38Speaker 1: because we've already seen so much growth and progression from
- 23:43Speaker 1: a long term perspective. Now, I want to say it's
- 23:46Speaker 1: a huge opportunity. Right, it's even brighter. There's one hundred
- 23:51Speaker 1: and eighteen biologics in the next decade that are losing
- 23:54Speaker 1: that patent protection. And remember I said in the beginning
- 23:57Speaker 1: that's how you can bring a biosimilar to market. So
- 24:00Speaker 1: we have one hundred and eighteen opportunities that equate to
- 24:03Speaker 1: a two hundred and thirty four billion dollar opportunity spreading
- 24:08Speaker 1: across thirteen broad therapeutic areas. This is pivotal to me.
- 24:13Speaker 1: This thirteen therapeutic areas is where it's really exciting because
- 24:18Speaker 1: biosimilars predominantly have been concentrated in immunology and oncology, and
- 24:24Speaker 1: the ability to reach other subsets of patients and provide
- 24:30Speaker 1: more treatment options, provide cost savings, that's super exciting.
- 24:35Speaker 2: Yeah, I mean two hundred and thirty four billion dollar opportunity.
- 24:40Speaker 3: Yeah, I mean, wow, I'm just.
- 24:42Speaker 2: Trying to wrap my head around that one hundred and
- 24:46Speaker 2: eighteen different biologics that could be available. So as you
- 24:51Speaker 2: go further here now that you know, advancing not only
- 24:55Speaker 2: talking about it with folks and trying to navigate maybe
- 24:59Speaker 2: help now the gate different whether it be independent pharmacists
- 25:04Speaker 2: or other people within healthcare trying to navigate the landscape
- 25:07Speaker 2: of biosimilars. What role is Cardinal Health playing in advancing
- 25:12Speaker 2: biosimilars and maybe getting that word out into the market
- 25:15Speaker 2: and talking about how this could be a two hundred
- 25:18Speaker 2: and thirty four billion dollar opportunity for folks.
- 25:22Speaker 1: Yeah, Cardinal's role here is increasing awareness of these cost
- 25:25Speaker 1: effective alternatives and educating stakeholders. We do see the value
- 25:31Speaker 1: of this market and its importance in funding future innovation
- 25:35Speaker 1: as we look at markets like selling gene where therapies
- 25:38Speaker 1: could be four million dollars for one dose, or we
- 25:42Speaker 1: know we have to find ways to bring savings back
- 25:45Speaker 1: into the system and biosimilars are one of those opportunities.
- 25:49Speaker 1: So it's a beautiful link between cost savings and innovation,
- 25:52Speaker 1: and we aim to partner and collaborate with all the
- 25:55Speaker 1: stakeholders within this healthcare industry to help drive this. The
- 26:00Speaker 1: next few years are exciting that this year alone is exciting.
- 26:05Speaker 1: There's many new molecules coming to market. For example, Denasamab
- 26:09Speaker 1: is a molecule that is expected to launch this summer,
- 26:12Speaker 1: and a lot of customers are asking questions about these products.
- 26:15Speaker 1: And at Cardinal, we're supporting our customers. We're helping them
- 26:18Speaker 1: find the answers in every way that we can. We
- 26:21Speaker 1: also have our website that has tons of resources, so
- 26:25Speaker 1: I'm traveling around the country as well as Frank Gregory
- 26:29Speaker 1: speaking on biosimilars spreading the message. So we're working hard
- 26:34Speaker 1: to keep that avenue of information flowing throughout the entire industry.
- 26:40Speaker 2: So, with this being the counter Talk podcast, and obviously
- 26:43Speaker 2: most of our audience are probably most likely independent pharmacists,
- 26:49Speaker 2: how can pharmacists add value to the future of biosimilars.
- 26:53Speaker 3: I think it's an important question.
- 26:55Speaker 2: Maybe pharmacists here that number two hundred and thirty four,
- 26:59Speaker 2: you know, billing to our to me like, all right,
- 27:01Speaker 2: how do I get.
- 27:02Speaker 3: Involved in this? What does it look like for the
- 27:04Speaker 3: future of the independent pharmacist.
- 27:07Speaker 1: Yeah, what we have learned in the last decade is
- 27:11Speaker 1: the value of the pharmacist in the biosimilar industry. They
- 27:14Speaker 1: are one of the most important stakeholders for biosimilars. Pharmacists
- 27:21Speaker 1: play critical role because they're in this interesting space where
- 27:25Speaker 1: they have the trust of a patient and a trust
- 27:29Speaker 1: of a provider. Because of their expertise and just their
- 27:33Speaker 1: role in general, they have this really great relationship with
- 27:37Speaker 1: patients and providers, so they're pivotal in the biosimilar conversation.
- 27:44Speaker 1: The pharmacists are educating the patients and the providers about biosimilars.
- 27:48Speaker 1: They're helping to build that trust and confidence in these products.
- 27:53Speaker 1: That acceptance of these products is what improves the market,
- 27:56Speaker 1: the sustainability and the adoption. So a pharmacist is key
- 28:01Speaker 1: and critical for this adoption in biosimilars to grow, and
- 28:05Speaker 1: we know that, so we've really started to focus more
- 28:09Speaker 1: on the role of the pharmacist. How can we partner
- 28:11Speaker 1: with our pharmacists, What resources do they need to help
- 28:15Speaker 1: drive biosimilar utilization. Another interesting role that a pharmacist can
- 28:21Speaker 1: take is around interchangeability. Some biosimilars come to market with
- 28:26Speaker 1: an interchangeability designation and some don't, and that does produce
- 28:30Speaker 1: some confusion in the market. There have been some misconceptions
- 28:34Speaker 1: if the interchangeable products are better than the ones that
- 28:37Speaker 1: are not interchangeable, which is not true. The products are all,
- 28:42Speaker 1: according to the FDA, highly similar and of the same caliber.
- 28:46Speaker 1: And I find that pharmacists tend to be the primary
- 28:50Speaker 1: stakeholder addressing those misconceptions and educating on interchangeability. The other
- 28:57Speaker 1: piece of a pharmacist is they can actually target that
- 29:00Speaker 1: education to the specific person they're talking with. So like
- 29:04Speaker 1: on our website, we're just we have vast amounts of education,
- 29:08Speaker 1: but it maybe isn't targeted. Like you're a provider, I'm
- 29:11Speaker 1: going to tell you this, you're a patient, I'm going
- 29:13Speaker 1: to tell you this. When a pharmacist is having a conversation,
- 29:16Speaker 1: they're targeting that education, making it relevant to the person
- 29:20Speaker 1: they're talking to. And we know that when information is
- 29:25Speaker 1: relevant and targeted, it's more effective. So the pharmacist is
- 29:30Speaker 1: I cannot tell you the emphasis we place on that stakeholder.
- 29:34Speaker 1: And then the very last thing is that they can
- 29:36Speaker 1: highlight the cost savings where it's appropriate. So it's really
- 29:41Speaker 1: multifactory what they can do for the biosimilar industry.
- 29:45Speaker 3: Now, yeah, I appreciate that insight I'm sure the listeners
- 29:47Speaker 3: do too.
- 29:47Speaker 2: I think that's amazing. So I'm going to put you
- 29:50Speaker 2: a little bit on the spot here, JC. I'm going
- 29:51Speaker 2: to give you your elevator pitch, if you will. So,
- 29:56Speaker 2: if someone, if I'm someone, or there's a stakeholder, or
- 29:59Speaker 2: if they're as a pharmacist or a doctor or whoever
- 30:03Speaker 2: it may be, if they're interested in buying or purchasing biosimilars,
- 30:08Speaker 2: why should they and why should.
- 30:11Speaker 3: They be jumping on board you know today?
- 30:13Speaker 2: So I'll give you give me your elevator pitsh on
- 30:16Speaker 2: why I should be buying biosimilars.
- 30:20Speaker 1: Okay, you should be buying biosimilars because it's increased treatment options.
- 30:25Speaker 1: When a patient is diagnosed with a disease, they don't
- 30:29Speaker 1: want one option, they want multiple treatment options. This is
- 30:32Speaker 1: that opportunity. They also could be cheaper, This could reduce
- 30:38Speaker 1: the costs, and that is an amazing opportunity as well.
- 30:41Speaker 1: And then lastly, this creates a strength and supply chain.
- 30:45Speaker 1: We have more drugs in the channel. If there's a
- 30:48Speaker 1: stockout on one product, we have a highly similar product.
- 30:51Speaker 1: So we're strengthening the abundance of the supply and inventory
- 30:55Speaker 1: in the country. That is why you should buy a biosimilar.
- 30:59Speaker 3: All right, well done, thank you.
- 31:04Speaker 2: All right, So today, you know, Dracy, thank you so much.
- 31:08Speaker 3: You we were we talked about a lot.
- 31:09Speaker 2: We talked about the genesis of biosimilars, the pathways that
- 31:15Speaker 2: are that are available now, the regulatory frameworks, the savings
- 31:21Speaker 2: within the healthcare system, one hundred and eighteen biosimilars coming
- 31:26Speaker 2: to fruition here pretty soon and with a two hundred
- 31:29Speaker 2: and thirty four billion dollar opportunity the pharmacists impact here
- 31:33Speaker 2: and and biosimilar is being just another great option for
- 31:38Speaker 2: treatment and possibly being cheaper.
- 31:39Speaker 3: So we covered a lot.
- 31:41Speaker 2: But I do want to give an opportunity for all
- 31:43Speaker 2: the listeners here to you. You kept referencing the ten
- 31:47Speaker 2: year Biosimilar Report, So anybody that's listening, if they're interested
- 31:51Speaker 2: in reading the report and really taking a deep dive,
- 31:53Speaker 2: where can they find it.
- 31:55Speaker 1: Listeners can head to our website at cardinal health dot
- 31:59Speaker 1: com back Splash Biosimilars and they can download the report
- 32:03Speaker 1: and learn more. And they can always email myself and
- 32:07Speaker 1: my team with any questions that they may have. We
- 32:09Speaker 1: would love to connect and help out.
- 32:12Speaker 2: So cardinalhealth dot com backslash biosimilar is correct.
- 32:15Speaker 3: Yes, yeah, thought it'd be pretty easy to remember.
- 32:18Speaker 2: And also the biosimilars team, you guys are going to
- 32:21Speaker 2: be at RBC to talk to potential customers that correct.
- 32:26Speaker 1: Yes, I will be running the booths dot by and
- 32:28Speaker 1: see me.
- 32:29Speaker 2: I think I'm going to stop by the booth and
- 32:31Speaker 2: see if you can sell me again on biosimilars.
- 32:33Speaker 3: I appreciate it.
- 32:34Speaker 1: That's great, all right.
- 32:37Speaker 2: So with all that said, I want to say thanks
- 32:39Speaker 2: to Dracy for providing her valuable, her valuable time and
- 32:42Speaker 2: taking us all to school on all things biosimilars. I
- 32:46Speaker 2: hope all of you learned as much as I did today.
- 32:48Speaker 2: Remember visit cardinalhealth dot com slash biosimilars to read that
- 32:51Speaker 2: report and get all the information you need.
- 32:53Speaker 3: And it's all of you.
- 32:54Speaker 2: Thanks for listening to today's episode of the Cardinal Health
- 32:57Speaker 2: counter Talk podcast.
- 32:58Speaker 3: As a reminder,